ZHONGZHIPHARM (03737) announced that the profit attributable to equity holders in 2025 was RMB 17.29 million, a year-on-year decrease of 81.8%.
Zhongzhi Pharmaceuticals (03737) announced its performance in 2025, with revenue of approximately 1.737 billion yuan, a year-on-year decrease of 21.6%; the profit attributable to equity holders of the company was 17.29 million yuan, a year-on-year decrease of 81.8%; earnings per share were 0.02 yuan.
ZHONGZHIPHARM (03737) announced its performance for the year 2025, with a revenue of approximately 1.737 billion yuan, a year-on-year decrease of 21.6%; the net profit attributable to equity holders of the company was 17.29 million yuan, a year-on-year decrease of 81.8%; earnings per share were 0.02 yuan.
Related Articles
Shenzhen UTIMES Intelligent Equipment (688638.SH) plans to launch a restricted stock incentive plan for 2026.
TOMSON GROUP (00258) released its annual performance, with a net profit attributable to shareholders of HK$791 million, an increase of 347.57% year-on-year.
US Stock Market Move | Destiny Tech100 (DXYZ.US) fell nearly 1% in early trading. The investment portfolio includes SpaceX.
Shenzhen UTIMES Intelligent Equipment (688638.SH) plans to launch a restricted stock incentive plan for 2026.
TOMSON GROUP (00258) released its annual performance, with a net profit attributable to shareholders of HK$791 million, an increase of 347.57% year-on-year.
US Stock Market Move | Destiny Tech100 (DXYZ.US) fell nearly 1% in early trading. The investment portfolio includes SpaceX.
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
